Profiles

Keywords
Last Name
Institution
 Back to Details

Connection

Nancy Reau to Humans

This is a "connection" page, showing publications Nancy Reau has written about Humans.

 
Connection Strength
  
 
 
1.225
  
  1. Reau N, Sulkowski MS, Thomas E, Sundaram V, Xu Q, Cheng WH, Marx SE, Hayes OA, Manthena SR, Chirikov V, Dylla DE, Brooks H, Carabino JM, Saab S. Epidemiology and Clinical Characteristics of Individuals with Hepatitis C Virus Infection in the United States, 2017-2019. Adv Ther. 2021 12; 38(12):5777-5790.
    View in: PubMed
    Score: 0.046
  2. Van J, Aloman C, Reau N. Potential Bias and Misconceptions in Liver Transplantation for Alcohol- and Obesity-Related Liver Disease. Am J Gastroenterol. 2021 10 01; 116(10):2089-2097.
    View in: PubMed
    Score: 0.046
  3. Kushner T, Reau N. Had Anyone Considered the Donors? Fertility and Pregnancy Outcomes Among Female Living Donors. Liver Transpl. 2021 09; 27(9):1235-1236.
    View in: PubMed
    Score: 0.045
  4. Kushner T, Reau N. Changing epidemiology, implications, and recommendations for hepatitis C in women of childbearing age and during pregnancy. J Hepatol. 2021 03; 74(3):734-741.
    View in: PubMed
    Score: 0.043
  5. Sulkowski M, Cheng WH, Marx S, Sanchez Gonzalez Y, Strezewski J, Reau N. Estimating the Year Each State in the United States Will Achieve the World Health Organization's Elimination Targets for Hepatitis C. Adv Ther. 2021 01; 38(1):423-440.
    View in: PubMed
    Score: 0.043
  6. Dieterich DT, Bernstein D, Flamm S, Pockros PJ, Reau N. Review article: a treatment algorithm for patients with chronic liver disease and severe thrombocytopenia undergoing elective medical procedures in the United States. Aliment Pharmacol Ther. 2020 10; 52(8):1311-1322.
    View in: PubMed
    Score: 0.042
  7. Orekondy N, Cafardi J, Kushner T, Reau N. HCV in Women and Pregnancy. Hepatology. 2019 11; 70(5):1836-1840.
    View in: PubMed
    Score: 0.040
  8. Serper M, Evon DM, Stewart PW, Lok AS, Amador J, Reeve BB, Golin CE, Fried MW, Reddy KR, Sterling RK, Sarkar S, Di Bisceglie AM, Lim JK, Nelson DR, Reau N. Medication Non-adherence in a Prospective, Multi-center Cohort Treated with Hepatitis C Direct-Acting Antivirals. J Gen Intern Med. 2020 04; 35(4):1011-1020.
    View in: PubMed
    Score: 0.040
  9. Ma K, Berger D, Reau N. Liver Diseases During Pregnancy. Clin Liver Dis. 2019 05; 23(2):345-361.
    View in: PubMed
    Score: 0.038
  10. Reau N, Kwo PY, Rhee S, Brown RS, Agarwal K, Angus P, Gane E, Kao JH, Mantry PS, Mutimer D, Reddy KR, Tran TT, Hu YB, Gulati A, Krishnan P, Dumas EO, Porcalla A, Shulman NS, Liu W, Samanta S, Trinh R, Forns X. Glecaprevir/Pibrentasvir Treatment in Liver or Kidney Transplant Patients With Hepatitis C Virus Infection. Hepatology. 2018 10; 68(4):1298-1307.
    View in: PubMed
    Score: 0.037
  11. Reau N. Pregnancy after liver transplantation: Can renal function quell the fear? Liver Transpl. 2018 05; 24(5):583-584.
    View in: PubMed
    Score: 0.036
  12. Soriano V, Young B, Reau N. Report from the International Conference on Viral Hepatitis - 2017. AIDS Rev. 2018 Jan-Mar; 20(1):58-70.
    View in: PubMed
    Score: 0.035
  13. Reau N, Nelson DR. HBV reactivation after HCV eradication: Deja Vu. Liver Int. 2017 07; 37(7):1088.
    View in: PubMed
    Score: 0.034
  14. Behara R, Reau N. Updates on hepatitis C virus therapy in the direct-acting antiviral era. Curr Opin Gastroenterol. 2017 May; 33(3):115-119.
    View in: PubMed
    Score: 0.034
  15. Jensen DM, Sebhatu P, Reau NS. Generic medications for hepatitis C. Liver Int. 2016 07; 36(7):925-8.
    View in: PubMed
    Score: 0.032
  16. Shiffman ML, Rustgi V, Bennett M, Forns X, Asselah T, Planas Vila R, Liu L, Pedrosa M, Moller J, Reau N. Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir With or Without Ribavirin in HCV-Infected Patients Taking Concomitant Acid-Reducing Agents. Am J Gastroenterol. 2016 06; 111(6):845-51.
    View in: PubMed
    Score: 0.031
  17. Desai AP, Reau N. The Burden of Rehospitalization for Patients With Liver Cirrhosis. Hosp Pract (1995). 2016; 44(1):60-9.
    View in: PubMed
    Score: 0.031
  18. Tran TT, Ahn J, Reau NS. ACG Clinical Guideline: Liver Disease and Pregnancy. Am J Gastroenterol. 2016 Feb; 111(2):176-94; quiz 196.
    View in: PubMed
    Score: 0.031
  19. Reau N, Fried MW, Nelson DR, Brown RS, Everson GT, Gordon SC, Jacobson IM, Lim JK, Pockros PJ, Reddy KR, Sherman KE. HCV Council--critical appraisal of data: recommendations for clinical practice in a rapidly evolving therapeutic landscape. Liver Int. 2016 Apr; 36(4):488-502.
    View in: PubMed
    Score: 0.030
  20. Teriaky A, Reau N. Evaluation of Hepatitis C Patients in the Direct-Acting Antiviral Era. Clin Liver Dis. 2015 Nov; 19(4):591-604, v.
    View in: PubMed
    Score: 0.030
  21. Reau NS, Jensen DM. Sticker shock and the price of new therapies for hepatitis C: is it worth it? Hepatology. 2014 Apr; 59(4):1246-9.
    View in: PubMed
    Score: 0.027
  22. Reau N. Finding the needle in the haystack: predicting mortality in pregnancy-related liver disease. Clin Gastroenterol Hepatol. 2014 Jan; 12(1):114-6.
    View in: PubMed
    Score: 0.026
  23. Satoskar R, Reau N. Potential consequences of healthcare recommendations: a focus on the U.S. Preventive Services Task Force. Hepatology. 2013 Jul; 58(1):422-7.
    View in: PubMed
    Score: 0.026
  24. Gaetano JN, Reau N. Hepatitis C: management of side effects in the era of direct-acting antivirals. Curr Gastroenterol Rep. 2013 Jan; 15(1):305.
    View in: PubMed
    Score: 0.025
  25. Mufti AR, Reau N. Liver disease in pregnancy. Clin Liver Dis. 2012 May; 16(2):247-69.
    View in: PubMed
    Score: 0.024
  26. Desai AP, Reau N. Naives, nonresponders, relapsers: who is there left to treat? Clin Liver Dis. 2011 Aug; 15(3):483-95.
    View in: PubMed
    Score: 0.023
  27. Reau N, Hamzeh FM, Lentz E, Zhou X, Jensen D. Characterization of nonrapid virologic response patients infected with HCV genotype 1 who may relapse after standard therapy with peginterferon plus ribavirin. J Viral Hepat. 2012 Feb; 19(2):94-102.
    View in: PubMed
    Score: 0.022
  28. Reau N, Satoskar R, Te H, DeVoss A, Elsen C, Reddy G, Mohanty S, Jensen D. Evaluation of early null response to pegylated interferon and ribavirin as a predictor of therapeutic nonresponse in patients undergoing treatment for chronic hepatitis C. Am J Gastroenterol. 2011 Mar; 106(3):452-8.
    View in: PubMed
    Score: 0.021
  29. Aronsohn A, Reau N. Long-term outcomes after treatment with interferon and ribavirin in HCV patients. J Clin Gastroenterol. 2009 Aug; 43(7):661-71.
    View in: PubMed
    Score: 0.020
  30. Reau N, Hadziyannis SJ, Messinger D, Fried MW, Jensen DM. Early predictors of anemia in patients with hepatitis C genotype 1 treated with peginterferon alfa-2a (40KD) plus ribavirin. Am J Gastroenterol. 2008 Aug; 103(8):1981-8.
    View in: PubMed
    Score: 0.018
  31. Singh NA, Reau N. Management of hepatitis B virus. J Antimicrob Chemother. 2008 Aug; 62(2):224-8.
    View in: PubMed
    Score: 0.018
  32. Reau NS, Jensen DM. Vanishing bile duct syndrome. Clin Liver Dis. 2008 Feb; 12(1):203-17, x.
    View in: PubMed
    Score: 0.018
  33. Chaillon A, Wynn A, Kushner T, Reau N, Martin NK. Cost-effectiveness of Antenatal Rescreening Among Pregnant Women for Hepatitis C in the United States. Clin Infect Dis. 2021 11 02; 73(9):e3355-e3357.
    View in: PubMed
    Score: 0.011
  34. Fix OK, Blumberg EA, Chang KM, Chu J, Chung RT, Goacher EK, Hameed B, Kaul DR, Kulik LM, Kwok RM, McGuire BM, Mulligan DC, Price JC, Reau NS, Reddy KR, Reynolds A, Rosen HR, Russo MW, Schilsky ML, Verna EC, Ward JW, Fontana RJ. American Association for the Study of Liver Diseases Expert Panel Consensus Statement: Vaccines to Prevent Coronavirus Disease 2019 Infection in Patients With Liver Disease. Hepatology. 2021 08; 74(2):1049-1064.
    View in: PubMed
    Score: 0.011
  35. McGuire FH, André K, Bradsher ML, Harrison D, Sterling RK, Reddy KR, Serper M, Golin CE, Reau N, Lim JK, Nelson DR, Sarkar S, Evon DM. Willingness to participate in research among black patients with liver disease: A national cross-sectional study. J Viral Hepat. 2021 07; 28(7):982-993.
    View in: PubMed
    Score: 0.011
  36. Serper M, Evon DM, Amador J, Stewart PW, Sarkar S, Lok AS, Sterling RK, Reeve BB, Golin CE, Rajender Reddy K, Lim JK, Reau N, Nelson DR, Di Bisceglie AM, Fried MW. Patient-reported outcomes 12 months after hepatitis C treatment with direct-acting antivirals: Results from the PROP UP study. Liver Int. 2021 04; 41(4):692-704.
    View in: PubMed
    Score: 0.011
  37. Asselah T, Zeuzem S, Reau N, Hwang P, Long J, Talwani R, Robertson MN, Haber BA. Efficacy and safety of elbasvir/grazoprevir for 12 weeks in people with hepatitis C virus infection aged 35 years or younger compared with older people: a retrospective integrated analysis. Curr Med Res Opin. 2020 08; 36(8):1325-1332.
    View in: PubMed
    Score: 0.010
  38. Evon DM, Sarkar S, Amador J, Lok AS, Sterling RK, Stewart PW, Reeve BB, Serper M, Reau N, Reddy KR, Di Bisceglie AM, Nelson DR, Golin CE, Lim JK, Fried MW. Reply to: "Patient-reported symptoms during direct-acting antiviral treatment: A real-life study in HIV-HCV coinfected patients (ANRS CO13 HEPAVIH)". J Hepatol. 2020 03; 72(3):592-593.
    View in: PubMed
    Score: 0.010
  39. Chaillon A, Rand EB, Reau N, Martin NK. Cost-effectiveness of Universal Hepatitis C Virus Screening of Pregnant Women in the United States. Clin Infect Dis. 2019 11 13; 69(11):1888-1895.
    View in: PubMed
    Score: 0.010
  40. Singal AK, Satapathy SK, Reau N, Wong R, Kuo YF. Hepatitis C remains leading indication for listings and receipt of liver transplantation for hepatocellular carcinoma. Dig Liver Dis. 2020 01; 52(1):98-101.
    View in: PubMed
    Score: 0.010
  41. Evon DM, Sarkar S, Amador J, Lok AS, Sterling RK, Stewart PW, Reeve BB, Serper M, Reau N, Rajender Reddy K, Di Bisceglie AM, Nelson DR, Golin CE, Lim JK, Fried MW. Patient-reported symptoms during and after direct-acting antiviral therapies for chronic hepatitis C: The PROP UP study. J Hepatol. 2019 09; 71(3):486-497.
    View in: PubMed
    Score: 0.010
  42. Evon DM, Stewart PW, Amador J, Serper M, Lok AS, Sterling RK, Sarkar S, Golin CE, Reeve BB, Nelson DR, Reau N, Lim JK, Reddy KR, Di Bisceglie AM, Fried MW. A comprehensive assessment of patient reported symptom burden, medical comorbidities, and functional well being in patients initiating direct acting antiviral therapy for chronic hepatitis C: Results from a large US multi-center observational study. PLoS One. 2018; 13(8):e0196908.
    View in: PubMed
    Score: 0.009
  43. Evon DM, Amador J, Stewart P, Reeve BB, Lok AS, Sterling RK, Di Bisceglie AM, Reau N, Serper M, Sarkar S, Lim JK, Golin CE, Fried MW. Psychometric properties of the PROMIS short form measures in a U.S. cohort of 961 patients with chronic hepatitis C prescribed direct acting antiviral therapy. Aliment Pharmacol Ther. 2018 Apr; 47(7):1001-1011.
    View in: PubMed
    Score: 0.009
  44. Hezode C, Reau N, Svarovskaia ES, Doehle BP, Shanmugam R, Dvory-Sobol H, Hedskog C, McNally J, Osinusi A, Brainard DM, Miller MD, Mo H, Roberts SK, O'Leary JG, Shafran SD, Zeuzem S. Resistance analysis in patients with genotype 1-6 HCV infection treated with sofosbuvir/velpatasvir in the phase III studies. J Hepatol. 2018 05; 68(5):895-903.
    View in: PubMed
    Score: 0.009
  45. Kanwal F, Bacon BR, Beste LA, Brill JV, Gifford AL, Gordon SC, Horberg MA, Manthey JG, Reau N, Rustgi VK, Younossi ZM. Hepatitis C Virus Infection Care Pathway-A Report From the American Gastroenterological Association Institute HCV Care Pathway Work Group. Gastroenterology. 2017 05; 152(6):1588-1598.
    View in: PubMed
    Score: 0.008
  46. Evon DM, Golin CE, Stewart P, Fried MW, Alston S, Reeve B, Lok AS, Sterling RK, Lim JK, Reau N, Sarkar S, Nelson DR, Reddy KR, Di Bisceglie AM. Patient engagement and study design of PROP UP: A multi-site patient-centered prospective observational study of patients undergoing hepatitis C treatment. Contemp Clin Trials. 2017 06; 57:58-68.
    View in: PubMed
    Score: 0.008
  47. Mikolajczyk AE, Farnan JM, McConville JF, Jensen DM, Reddy KG, Te HS, Reau N, Aronsohn AI. Novel educational interventions in residency increase knowledge of chronic liver disease and career interest in hepatology. Hepatology. 2016 12; 64(6):2210-2218.
    View in: PubMed
    Score: 0.008
  48. Lawitz E, Reau N, Hinestrosa F, Rabinovitz M, Schiff E, Sheikh A, Younes Z, Herring R, Reddy KR, Tran T, Bennett M, Nahass R, Yang JC, Lu S, Dvory-Sobol H, Stamm LM, Brainard DM, McHutchison JG, Pearlman B, Shiffman M, Hawkins T, Curry M, Jacobson I. Efficacy of Sofosbuvir, Velpatasvir, and GS-9857 in Patients With Genotype 1 Hepatitis C Virus Infection in an Open-Label, Phase 2 Trial. Gastroenterology. 2016 11; 151(5):893-901.e1.
    View in: PubMed
    Score: 0.008
  49. Younossi ZM, Stepanova M, Sulkowski M, Foster GR, Reau N, Mangia A, Patel K, Bräu N, Roberts SK, Afdhal N, Nader F, Henry L, Hunt S. Ribavirin-Free Regimen With Sofosbuvir and Velpatasvir Is Associated With High Efficacy and Improvement of Patient-Reported Outcomes in Patients With Genotypes 2 and 3 Chronic Hepatitis C: Results From Astral-2 and -3 Clinical Trials. Clin Infect Dis. 2016 10 15; 63(8):1042-1048.
    View in: PubMed
    Score: 0.008
  50. Gaetano JN, Micic D, Aronsohn A, Reddy G, Te H, Reau NS, Jensen D. The benefit of paracentesis on hospitalized adults with cirrhosis and ascites. J Gastroenterol Hepatol. 2016 May; 31(5):1025-30.
    View in: PubMed
    Score: 0.008
  51. Foster GR, Afdhal N, Roberts SK, Bräu N, Gane EJ, Pianko S, Lawitz E, Thompson A, Shiffman ML, Cooper C, Towner WJ, Conway B, Ruane P, Bourlière M, Asselah T, Berg T, Zeuzem S, Rosenberg W, Agarwal K, Stedman CA, Mo H, Dvory-Sobol H, Han L, Wang J, McNally J, Osinusi A, Brainard DM, McHutchison JG, Mazzotta F, Tran TT, Gordon SC, Patel K, Reau N, Mangia A, Sulkowski M. Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection. N Engl J Med. 2015 Dec 31; 373(27):2608-17.
    View in: PubMed
    Score: 0.008
  52. Muir AJ, Poordad F, Lalezari J, Everson G, Dore GJ, Herring R, Sheikh A, Kwo P, Hézode C, Pockros PJ, Tran A, Yozviak J, Reau N, Ramji A, Stuart K, Thompson AJ, Vierling J, Freilich B, Cooper J, Ghesquiere W, Yang R, McPhee F, Hughes EA, Swenson ES, Yin PD. Daclatasvir in combination with asunaprevir and beclabuvir for hepatitis C virus genotype 1 infection with compensated cirrhosis. JAMA. 2015 May 05; 313(17):1736-44.
    View in: PubMed
    Score: 0.007
  53. Sengupta S, Wroblewski K, Aronsohn A, Reau N, Reddy KG, Jensen D, Te H. Screening for Zinc Deficiency in Patients with Cirrhosis: When Should We Start? Dig Dis Sci. 2015 Oct; 60(10):3130-5.
    View in: PubMed
    Score: 0.007
  54. Desai AP, Satoskar R, Appannagari A, Reddy KG, Te HS, Reau N, Meltzer DO, Jensen D. Co-management between hospitalist and hepatologist improves the quality of care of inpatients with chronic liver disease. J Clin Gastroenterol. 2014 Apr; 48(4):e30-6.
    View in: PubMed
    Score: 0.007
  55. Aronsohn A, Reau N, Jensen D. Preparing for the uncertain yet inevitable: off-label combinations of antiviral agents in hepatitis C virus. Hepatology. 2014 May; 59(5):1688-91.
    View in: PubMed
    Score: 0.007
  56. Te HS, Dasgupta KA, Cao D, Satoskar R, Mohanty SR, Reau N, Millis JM, Jensen DM. Use of immune function test in monitoring immunosuppression in liver transplant recipients. Clin Transplant. 2012 Nov-Dec; 26(6):826-32.
    View in: PubMed
    Score: 0.006
  57. Marcellin P, Reau N, Ferenci P, Hadziyannis S, Messinger D, Tatsch F, Jensen D. Refined prediction of week 12 response and SVR based on week 4 response in HCV genotype 1 patients treated with peginterferon alfa-2a (40KD) and ribavirin. J Hepatol. 2012 Jun; 56(6):1276-82.
    View in: PubMed
    Score: 0.006
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.